KRAS and neoplasm: Tumors with mutated KRAS are likely to respond better due to upregulated PD-L1 expression and immune cell infiltration, as opposed to EGFR and ALK-driven tumors, which typically have “cold” tumor microenvironments with fewer immune cells [234,238,239].